January 30, 2023 South San Francisco, CA–(business wire)–Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology agency focused on the acquisition, enchancment and commercialization of contemporary therapies that rework victims’ lives, at current launched that it has entered into its enchancment pipeline. We equipped an change on the street and our enterprise outlook for 2023. We’ll prioritize capital sources in course of accelerating our enchancment pipeline by way of opportunistic licensing and acquisition of clinical-stage property specializing in debilitating and unusual sicknesses. Quince plans to license its bone-targeted drug platform and precision bone improvement molecule NOV004, designed to hurry up fracture restore in victims with fractures and osteogenesis imperfecta.

“We contemplate our optimum improvement plan is to direct capital, drug enchancment and firm sources in course of licensing and shopping for clinical-stage property. We’re actively on the lookout for partnership alternate options that focus on the growth of the company,” said Dirk Thye, M.D., Ph.D., Chief Govt Officer of Quince.”With a strong stability sheet, optimized cash runway and expert Backed by a strong enchancment employees, Quince is successfully positioned to execute our plans as we work diligently to ascertain, contemplate and full the licensing and acquisition of commercially viable property. I’ve.”

Key highlights of the company’s strategic improvement plan embrace:

Prioritize pipeline enlargement by way of in-licensing and acquisitions

• A proactive due diligence course of to ascertain and contemplate viable clinical-stage property for licensing and acquisition.

• We’re trying to find clinical-stage property primarily specializing in the therapeutic area of ​​debilitating and unusual sicknesses.

• Potential asset targets require compelling data, well-defined enterprise alternate options, and surroundings pleasant medical and regulatory enchancment pathways.

• Potential to leverage the administration employees’s collective prior experience throughout the enchancment and commercialization of over 25 accredited therapeutics.

story continues

Bone-targeted drug platform and out-licensing of precision bone improvement molecule NOV004

• We intention to license our bone-targeted drug platform and the precision bone improvement molecule NOV004.

• The precision bone improvement molecule NOV004 is an anabolic peptide designed to precisely aim and give attention to the fracture site, resulting in improved bone density, power, and speedy therapeutic, as demonstrated in in depth preclinical analysis. finish in a speedy enhance.

• NOV004 has completed all IND-ready analysis together with a worthwhile pre-IND meeting with the U.S. Meals and Drug Administration.

• We’ll set up companions and begin licensing efforts immediately, with the aim of ending the tactic by the highest of 2023.

Aggressive positioning with a strong stability sheet

• Strong cash place of roughly $94 million in cash, equivalents and marketable securities as of December 31, 2022.

• Essential cash runway to assist pipeline enlargement by way of licensing and acquisitions and to fund capital and operational expenditure by way of not lower than 2028.

• Excluding the impression of firm restructuring and potential enterprise enchancment actions, annual capital and dealing payments in 2023 are anticipated to be roughly $11 million.

The company has not accomplished getting ready its fourth quarter or full 12 months 2022 financial statements. Cash, cash equivalents and investments supplied as of December 31, 2022 are preliminary, unaudited, and subsequently inherently not sure and matter to change. The company is ending his 2022 financial outcomes. Quince is throughout the strategy of ending the company’s common year-end closing and consider procedures for the fiscal 12 months as of and ended December 31, 2022, and is not assured of final outcomes for this period. not. No change from these preliminary unaudited portions. The Agency’s unbiased registered public accounting company did not audit, consider, edit or course of the preliminary data for the fourth quarter and 12 months ended December 31, 2022.

About Quince Therapeutics

Quince Therapeutics is a biotechnology agency focused on shopping for, rising and commercializing trendy treatments that rework the lives of victims affected by debilitating and unusual sicknesses. The company is actively on the lookout for participating clinical-stage property on the market for in-licensing and acquisition to extend its enchancment pipeline. For additional data, see: www.quincetx.com Observe Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter. Pursuits regarding in-licensing and acquisition alternate options is also directed to bd@quincetx.com.

Forward-Wanting Statements

Statements on this data launch embody “forward-looking statements” that include vital risks and uncertainties. Forward-looking statements contained on this data launch are outlined as “contemplate,” “depend on,” “intend,” “objective,” “will,” “could,” “could,” “estimate, Phrases like “plan”, “potential”, “search”, “discover”. Examples of forward-looking statements embrace, amongst completely different points, statements in regards to the company’s cash place. Expectations regarding timing related to bone-targeted drug platform and his NOV004 licensing plan. Potential to ascertain quite a few partnership alternate options to extend the occasion pipeline by way of licensing and acquisition of clinical-stage property. Worth monetary financial savings and related payments. Forward-looking statements are based on Quince’s current expectations and are matter to inherent uncertainties, risks and assumptions which might be troublesome to predict and may set off exact outcomes to range materially from the company’s expectations. In addition to, positive forward-looking statements are based on assumptions about future events that will not present to be appropriate. Components that will set off exact outcomes to range embrace the risks described throughout the half entitled “Menace Components” throughout the Agency’s Quarterly Report on Variety 10-Q filed with the SEC on November 9, 2022. and uncertainties. and completely different tales filed with the SEC. The forward-looking statements contained on this data launch are made as of this date and Quince would not undertake any obligation to exchange such data, in addition to as required by related regulation. enhance.

View provide mannequin at businesswire.com: https://www.businesswire.com/news/home/20230130005565/en/

contact sort out

Stacy Lohan
Quince Therapeutics, Inc.
Vice President, Firm Communications and Investor Relations
ir@quincetx.com